Introduction

There is increase pressure to make cost

Emerging technologies through innovation 04 effective product is the single most issue
create valuable services as biotechnology is
the a driver in delivering promises made by
01 faced by global biotechnology industry

life science
There is need of holistic view to address the

It promises to transform existence in 3 05 challenges and strong linkages between

biotechnology and pharmaceutical
ways i.e. basis of life, basis of living and
basis of living system
02
The reason why venture capital and deal

06 making not able to push forward the

biotechnology is its low R&D productivity
Healthcare is in crisis and
Biopharmaceuticals need to leverage
biotechnology to address the crisis.
03 Effective development and application of

07 technology requires integration, driven by

specialisation & fragmentation
Why cooperative strategy?
Cooperative strategy is the planning in which two or more firm work together to achieve common objective

Biopharma underperforming in terms of competitiveness & the symptoms are slowdown

in output of new drugs, slow growth, poor financing and low R&D productivity.

There is slow growth, stagnant productivity, increasing price pressure and declining
profits adds the reason to list

So there should be innovation and rising cost in R&D needs to be moderated by the
cooperative strategies

Also the major challenges are how to finance risky investment, how to learn fast to
keep pace with advances in drug science knowledge and to integrate capabilities
across broad spectrum

Hence, the emerging situations demands cooperative strategies and more contribution
from more capable firms yet underperforming in India and Japan.

This can attribute to their capabilities and create & protect the favorable context through
intellectual property and legal system and the existing crisis can be addressed